Calmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company's medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company's technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company's subsidiary is Vector Vision, Inc.
Industry, Sector and Symbol:
- Market Cap: $3.17 million
- Outstanding Shares: 28,787,000
- 50 Day Moving Avg: $0.12
- 200 Day Moving Avg: $0.12
- 52 Week Range: $0.07 - $0.23
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $1.31 million
- Price / Sales: 2.42
- Book Value: ($0.44) per share
- Price / Book: -0.25
- Average Volume: 12,876 shs.
- Beta: 0.05
- Short Ratio: 3.99
Frequently Asked Questions for Competitive Technologies (OTCMKTS:CTTC)
What is Competitive Technologies' stock symbol?
Competitive Technologies trades on the OTCMKTS under the ticker symbol "CTTC."
How were Competitive Technologies' earnings last quarter?
Competitive Technologies Inc. (OTCMKTS:CTTC) announced its quarterly earnings data on Monday, November, 24th. The company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.02. View Competitive Technologies' Earnings History.
Who are some of Competitive Technologies' key competitors?
Some companies that are related to Competitive Technologies include Rosetta Genomics (ROSG), Kitov Pharmaceuticals Holdings (KTOV), Strata Skin Sciences (SSKN), NeuroMetrix (NURO), Windtree Therapeutics (WINT), Critical Outcome T (COTQF), Affymax (AFFY), Adeptus Health (ADPT), Bayer AG (BAYRY), DNIB Unwind (BIND), Echo Therapeutics (ECTE), ELEKTA (EKTAY), Epirus Biopharmaceuticals (EPRS), Essilor International SA (ESLOY), Fresenius SE (FSNUY), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX) and Parnell Pharmaceuticals Holdings Ltd (PARN).
Who are Competitive Technologies' key executives?
Competitive Technologies' management team includes the folowing people:
- Peter F. Brennan, Independent Chairman of the Board
- Conrad F. Mir, President, Chief Executive Officer, Director
- Thomas P. Richtarich, Chief Financial Officer
- Stephen J. D'Amato M.D., Chief Medical Officer
- Carl D. O'Connell, Director
- Rustin R. Howard, Independent Director
How do I buy Competitive Technologies stock?
Shares of Competitive Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Competitive Technologies' stock price today?
MarketBeat Community Rating for Competitive Technologies (OTCMKTS CTTC)MarketBeat's community ratings are surveys of what our community members think about Competitive Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Competitive Technologies stock can currently be purchased for approximately $0.11.
Consensus Ratings for Competitive Technologies (OTCMKTS:CTTC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Competitive Technologies (OTCMKTS:CTTC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Competitive Technologies (OTCMKTS:CTTC)Earnings History by Quarter for Competitive Technologies (OTCMKTS CTTC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Competitive Technologies (OTCMKTS:CTTC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Competitive Technologies (OTCMKTS:CTTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Competitive Technologies (OTCMKTS:CTTC)
Insider Ownership Percentage: 17.50%Insider Trades by Quarter for Competitive Technologies (OTCMKTS:CTTC)
Institutional Ownership Percentage: 0.17%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/27/2012||Richard D Hornidge||Director||Buy||2,500||$0.59||$1,475.00|| |
|9/4/2012||Stan Yarbro||Director||Buy||8,000||$0.88||$7,040.00|| |
Headline Trends for Competitive Technologies (OTCMKTS:CTTC)
Latest Headlines for Competitive Technologies (OTCMKTS:CTTC)
|Calmare Therapeutics Board of Directors Changes|
finance.yahoo.com - February 23 at 4:34 PM
|CALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi|
biz.yahoo.com - February 23 at 4:34 PM
|Calmare Therapeutics Medical Device and Peripherals Now Listed for Sale on GSA Advantage!(R) Web Portal|
finance.yahoo.com - January 26 at 5:45 PM
|Calmare Therapeutics Reports Third Quarter 2016 Results|
finance.yahoo.com - January 3 at 12:42 PM
|Manitok Energy Inc. Announces a New Production Milestone Exceeding 7,100 boe/d and Two Additional Well Test Results|
www.theglobeandmail.com - December 8 at 8:53 AM
|Amazon Is A Must-Own Hedge Against Traditional Retail Company Headwinds|
seekingalpha.com - December 8 at 8:53 AM
|CALMARE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Discl|
biz.yahoo.com - November 21 at 4:47 PM
|Calmare Therapeutics to Present at the 5th Annual SeeThruEquity Microcap Investor Conference|
finance.yahoo.com - May 25 at 1:00 PM
|Calmare Therapeutics Incorporated Uplists|
finance.yahoo.com - May 23 at 9:15 AM
|Calmare Therapeutics Reports First Quarter 2016 Results|
finance.yahoo.com - May 19 at 2:50 PM
|Calmare Therapeutics Reports Year-End 2015 Results|
finance.yahoo.com - April 19 at 2:53 PM
|CALMARE THERAPEUTICS INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - April 14 at 5:34 PM
|CALMARE THERAPEUTICS INC Financials|
finance.yahoo.com - March 8 at 1:04 PM
|Calmare Therapeutics Reports Third Quarter 2015 Results|
finance.yahoo.com - March 2 at 1:00 PM
|CALMARE THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - March 1 at 9:28 AM
|Calmare Therapeutics Awarded $15 Million General Supply Order Contract|
finance.yahoo.com - February 18 at 12:12 PM
|Calmare Therapeutics Incorporated Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer|
finance.yahoo.com - February 17 at 2:45 PM
|Calmare Therapeutics Discusses Complaint Settlement|
finance.yahoo.com - February 4 at 10:24 AM
|CALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - January 15 at 5:03 PM
|CALMARE THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss|
biz.yahoo.com - October 23 at 3:58 PM
|Calmare Therapeutics Incorporated to Present at the Robins Equity Research Round-up Conference|
finance.yahoo.com - October 7 at 12:30 PM
|CALMARE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State|
biz.yahoo.com - September 25 at 11:36 AM
|Calmare Therapeutics G.S.A. Contract Extended Through the First Quarter of 2016|
finance.yahoo.com - September 16 at 1:16 PM
Competitive Technologies (CTTC) Chart for Friday, July, 21, 2017